IEFFICACY OF INDAPAMIDE AND VALSARTAN COMBINED THERAPY PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC DISORDERS

Aim of the study: to study antihypertensive and organ-protective efficacy of indapamide and valsartan combined therapy hypertensive patients with high cardiovascular risk and metabolic disorders. Methods: The studyincluded 37 patients with stage I-III hypertension (ESH 2007), with an average age of 47.67±10.02 years, 48.6% men and 51.4% woman. Blood pressure was measured by Korotkov method. All patients were performed by M- and B-mode echocardiography. Flow-mediated endothelium dependent vasodilatation was measured during reactive hyperaemia due to 5 minute brachial occlusion.A 7.5 MHz highresolution ultrasound was used to measure carotid artery intimaemedia thickness (IMT). Blood lipid and glucose level, serum creatinin and uric acid level were estimated by enzyme assay method on biochemical analyzer “Daytona TM”. Results: 12-weekly combined therapy with indapamide and valsartan were shown very good antihypertensive efficacy in average daily doses 2.5 mg and 80±40.6 mg respectively, with reducing average blood pressure on 19.7±7.0% and attained goal level of BP in 92% cases. During the treatment were found significantly regress of left ventricular hypertrophy by reducing left ventricular mass index on 16.2±11.3%, effective vasoprotection, without significantly changes of metabolic disorders, which characterized indapamide and valsartan combination like metabolic neutral drug combination. Conclusion: Indapamide and valsartan combined therapy characterize with high antihypertensive, cardio- and vasoprotective efficacy andmetabolic neutrality choosing for treatment hypertensive patients with high cardiovascular risk and metabolic disorders.

hypertehsion, indapamide, valsartan, combination therapy, артериальная гипертензия, индапамид, валсартан, комбинированная терапия

1. Cheung B.M., Ong K.L., Man Y.B., et al. Prevalence, awareness, treatment and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J ClinHypertens 2002; 8: 93-98

2. Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Журнал «Системные гипертензии» 2010; 3: 5-26

3. Barrios V., Escobar C., Calderon A., et al. CONTROLRISK Investigators. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK Study. J Hum Hypertens 2007; 21: 479-485

4. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977; 55: 613-618

5. Laurent S., Lacolley P., Brunei P. Et al. Flow-dependent vasodilatations of brachial artery in essential hypertension. Am J Physiology 1990; 258: H1004-H1011

6. Bataillard A., Schiavi P., Sassard J., et al. Pharmacological properties of indapamide. Clin. Pharmacol. 1999; V 37, Suppl. 1: 7-12

7. Трисветова Е.Л., Бова А.А. Тиазидные и тиазидоподобные диуретики в лечении артериальной гипертензии. Клин. Медицина 2003; 3: 4-8

8. Gosse P., Sheridan D.J., Lannard F. Regression of left ventricular hypertrophy in patients treated with indapamide SR 1.5mg versus enalapril 20mg: the LIVE Study. J Hypertens 2000; 18: 1465-1475

9. Marre M., Puig J.G., Kokot F., et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613-1622

10. Abbou C. The efficacy and tolerance of indapamide in essential hypertension: a multicenter study in 981 patients. Curr Med Res Opin 1985; 9: 494-499

11. Jenningz G., Woug J. Regression of left ventricular hypertrophy in hypertension: changing patterns with successive metaanalysis. J Hypertens 1998; 16: 29-34

12. Spense J.D., Huff M., Barnett V.A. Effect of Indapamide versus Hydrochlorthiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. Can J ClinPharmacol 2000; 7: 32-37

13. Amery A., et al. Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. Lancet 1978; 1: 681-683

14. Стрюк Р.И. Обоснованность использования сартанов у больных артериальной гипертензией. Системные гипертензии 2009; 4: 38-42

15. Mallaco E., Santonastaso M., Vari N.A., et al. Comparison of valsartan 160mg with lizinopril 20mg, given as monotherapy or in combination with diuretic, for the treatment of hypertension: the Blood Pressure Rtduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. ClinTher 2004; 26: 855-865

16. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Laset 2004; 363: 2022-2031

17. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675

18. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906

19. Mochizuki S., Dahlof B., Shimizu M et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lanset 2007; 369: 1431-1439

20. Марцевич С.Ю., Лукина Ю.В., Дмитриева Н.А. и соавт. Сравнительное изучение эффективности и переносимости дженерического и оригинального препаратов валсартан в виде монотерапии или в комбинации с гидрохлортиазидом и бисопрололом у больных артериальной гипертензией 1-2 степени и метаболическим синдромом. Рациональная Фармакотерапия в Кардиологии 2012; 8: 17-22

21. Грачев А.В., Аляви А.Л., Мостовщиков С.Б. и соавт. К вопросу о гемодинамической норме в кардиологических исследованиях. Медицинский журнал Узбекистана 2001; 2-3: 12-16